Association betweenHLA‐B*4001and Lipodystrophy among HIV‐Infected Patients from Thailand Who Received a Stavudine‐Containing Antiretroviral Regimen
Clinical Infectious Diseases2010Vol. 50(4), pp. 597–604
Citations Over TimeTop 10% of 2010 papers
Wittaya Wangsomboonsiri, Surakameth Mahasirimongkol, Soranun Chantarangsu, Sasisopin Kiertiburanakul, Angkana Charoenyingwattana, Surat Komindr, Chupong Thongnak, Taisei Mushiroda, Yusuke Nakamura, Wasun Chantratita, Somnuek Sungkanuparph
Abstract
HLA-B*4001 is a strong genetic risk factor for stavudine-associated lipodystrophy in HIV-infected patients in Thailand. HLA-B*4001 may be used as a genetic marker to predict which patients will develop stavudine-associated lipodystrophy, to avoid or shorten the duration of stavudine use. This finding needs to be confirmed in further replication studies.
Related Papers
- → Prevalence of Lipoatrophy and Mitochondrial DNA Content of Blood and Subcutaneous Fat in HIV-1-Infected Patients Randomly Allocated to Zidovudine- or Stavudine-Based Therapy(2004)72 cited
- → Recovery From Lipodystrophy in HIV–infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor–based Antiretroviral Therapy(2011)19 cited
- → Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India(2014)15 cited
- → Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine(2012)13 cited
- → Lipoatrophy and mitochondrial DNA assays: see all, know all?(2004)6 cited